B. HARİBABU, P. Rama Krishna VENİ, K. Bala Murali KRİSHNA, K. Lakshmi PRAMEELA

RP-HPLC Estimation of Alogliptin and Pioglitazone Simultaneously in Combined Tablet Dosage Forms

A high performance liquid chromatographic method was developed to quantify alogliptin and pioglitazone simultaneously in bulk and combined tablet dosage form. The chromatographic analysis was done on a Zorbax C8 column (150 mm x 4.6 mm internal diameter, 5 μm particle size) with a mobile phase of 0.1 M ammonium acetate and methanol (50:50, v/v) at 1.0 mL/min. The effluents were monitored at 248 nm and the retention time of alogliptin and pioglitazone were 2.883 min and 4.329 min, respectively. Calibration curves were linear from 6.25-18.75 μg/mL for alogliptin and 11.25-33.75 μg/mL for pioglitazone. The LOD and LOQ values for alogliptin were 0.047 and 0.157 μg/mL, respectively; corresponding values for pioglitazone were 0.085 and 0.284 μg/ mL, respectively. The precision for alogliptin and pioglitazone was in the range of 0.094-0.303% and 0.072-0.239%, respectively, with corresponding accuracy of 99.450-99.692% and 100.184-100.422%. The developed and validated method was successfully applied for the simultaneous determination of alogliptin and pioglitazone in tablet formulation.

PDF

___

Jarvis CI, Cabrera A, Charron D. Alogliptin: a new dipeptidylpeptidase-4 inhibitor for type 2 diabetes mellitus. AnnPharmacother 2013; 47: 1532-9.

Marino AB, Cole SW. Alogliptin: safety, efficacy and clinicalimplications. J Pharm Pract 2015; 28: 99-106.

Golightly LK, Drayna CC, McDermott MT. Comparativeclinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.Clin Pharmacokinet 2012; 51: 501-14.

Cyrus VD, Vijay S. Pioglitazone in the Treatment of Type2 Diabetes: Safety and Efficacy Review. Clin Med InsightsEndocrinol Diabetes 2010; 3: 43-51.

Brunetti L, Kalabalık J. Management of Type-2 diabetesmellitus in adults. Focus on individualizing non-insulintherapies. P & T 2012; 37: 687-96.

van Raalte DH, van Genugten RE, Eliasson B, Moller-GoedeDL, Mari A, Tura A, Wilson C, Fleck P, Taskinen MR, SmithU, Diamant M. The effect of alogliptin and pioglitazonecombination therapy on various aspects of β-cell function inpatients with recent-onset type 2 diabetes. Eur J Endocrinol2014; 170: 565-74.

Julio R, Silvio EI, Jochen S, Penny RF, Craig AW, Qais M.Initial combination therapy with alogliptin and pioglitazonein drug-naive patients with type 2 diabetes. Diabetes Care2010; 33: 2406-8.

ht t p : / / www. fd a . gov / Ne wsEv e nt s / Ne w s ro om/PressAnnouncements/ucm336942.htm

Raval K, Srinivasa U. First order derivative and dualwavelength spectrophotometry methods development andvalidation for simultaneous estimation. Int J Pharm PharmaSci 2014; 6: 730-8.

Anusha M, Manzoor A, Satishkumar SA, Vijaya KCA.Simultaneous estimation of alogliptin and piogliazone in bulkand combined tablet dosage form by UV-spectrophotometricmethods. Int J Uni Pharma Bio Sci 2014; 3: 363-76.

Komal S, Amrita P. Development and validation of HPTLCmethod for simultaneous estimation of alogliptin benzoateand pioglitazone hydrochloride in bulk drugs and combineddosage forms. Int J Pharma Res Rev 2015; 4: 35-42.

Raval K, Srinivasa U. Development and validation of HPLCmethod for the simultaneous estimation of pioglitazone andalogliptin in bulk and dosage form. Int J Cur Res 2014; 6:10201-7.

Neelima B, Kumar PR, Bindu VH, Prasad YR. A validatedstability indicating RP-HPLC method for simultaneousdetermination of alogliptine and pioglitazone in bulk andpharmaceutical formulations. Int J Pharm 2014; 4: 458-64.

Manzoor A, Anusha M, Satishkumar SA, Kuppast IJ,Siddalingaswamy MS, Ravi MC. RP-HPLC methoddevelopment and validation for simultaneous estimation ofalogliptin and pioglitazone in combined tablet dosage form.World J Pharm Pharm Sci 2015; 4: 863-74.

Mokhtar MM, Sherin FH, Fotouh RM, Mona MA.Development and validation of a reversed phase HPLCmethod for simultaneous determination of antidiabetic drugsalogliptin benzoate and pioglitazone HCl. Der PharmaciaSinica 2016; 7: 32-40.

International Conference on Harmonization, Validationof Analytical Procedure, Text and Methododlogy Q2 (R1),IFMA, Geneva, Switzerland, 2005.